Bicalutamide
- Generic Name
- Bicalutamide
- Brand Names
- Casodex
- Drug Type
- Small Molecule
- Chemical Formula
- C18H14F4N2O4S
- CAS Number
- 90357-06-5
- Unique Ingredient Identifier
- A0Z3NAU9DP
- Background
Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor.
- Indication
Bicalutamide is indicated in combination with a luteinizing hormone-releasing hormone (LHRH) agonist for the treatment of Stage D2 metastatic carcinoma of the prostate.
- Associated Conditions
- Metastatic stage D2 Prostatic carcinoma
A Study of Definitive Therapy to Treat Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- Procedure: ProstatectomyRadiation: Radiation
- First Posted Date
- 2016-03-23
- Last Posted Date
- 2022-08-04
- Target Recruit Count
- 26
- Registration Number
- NCT02716974
- Locations
- 🇺🇸
Sibley Memorial Hospital, Washington, District of Columbia, United States
🇺🇸Johns Hopkins School of Medicine - Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
FDHT PET and Bicalutamide in Metastatic Breast Cancer
- First Posted Date
- 2016-03-03
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 22
- Registration Number
- NCT02697032
- Locations
- 🇳🇱
University Medical Center Groningen, Groningen, Netherlands
Endocrine Therapy With or Without Cryoablation for Stage IV Prostate Cancer
- Conditions
- Stage IV Prostate Cancer
- Interventions
- First Posted Date
- 2015-11-26
- Last Posted Date
- 2017-06-12
- Target Recruit Count
- 120
- Registration Number
- NCT02615223
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients
- Conditions
- Cancer of Prostate
- Interventions
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2022-03-29
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 29
- Registration Number
- NCT02614859
- Locations
- 🇺🇸
Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸National Cancer Institute, Bethesda, Maryland, United States
Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)
- Conditions
- Metastatic Breast Cancer (MBC)
- Interventions
- First Posted Date
- 2015-11-16
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 46
- Registration Number
- NCT02605486
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
Cryoablation Therapy or Radiotherapy Therapy for Stage III Prostate Cancer
- Conditions
- Stage III Prostate Cancer
- Interventions
- Procedure: Cryoablation therapyRadiation: External beam radiation therapyDrug: luteinizing-hormone releasing-hormone (LHRH) agonist
- First Posted Date
- 2015-11-16
- Last Posted Date
- 2017-06-12
- Target Recruit Count
- 240
- Registration Number
- NCT02605226
- Locations
- 🇨🇳
Tianjin Medical University Cancer Hospital, Tianjin, Tianjin, China
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
- Conditions
- Bone MetastasesProstate CancerProstate Neoplasms
- Interventions
- First Posted Date
- 2015-10-21
- Last Posted Date
- 2022-07-11
- Lead Sponsor
- Ajjai Alva, MD
- Target Recruit Count
- 16
- Registration Number
- NCT02582749
- Locations
- 🇺🇸
University of Michigan Health System, Ann Arbor, Michigan, United States
🇺🇸Clement J. Zablocki VA Medical Center, Milwaukee, Wisconsin, United States
🇺🇸Illinois CancerCare, P. C., Peoria, Illinois, United States
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
- Conditions
- Prostatic Neoplasms
- Interventions
- Radiation: 74-80 Grays (units of radiation)
- First Posted Date
- 2015-08-24
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Aragon Pharmaceuticals, Inc.
- Target Recruit Count
- 1503
- Registration Number
- NCT02531516
Clinical Trial to Study Quality of Life in Prostate Cancer Patients by Randomizing Anti-androgen Versus Total Androgen Blockage Prior to Curative Intended Radiation Therapy
- First Posted Date
- 2015-03-06
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- Karolinska University Hospital
- Target Recruit Count
- 110
- Registration Number
- NCT02382094
Micro RNAs to Predict Response to Androgen Deprivation Therapy
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 42
- Registration Number
- NCT02366494
- Locations
- 🇺🇸
Froedtert Hospital, Milwaukee, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.